bluuebunny/crossref_metadata_2025_split huggingface dataset:
Metastatic rhabdomyosarcoma and histologically similar tumors in childhood: A retrospective european multi‐center analysis
Authors: Koscielniak Ewa , Rodary Chantal , Flamant Francoise , Carli Modesto , Treuner Jörn , Pinkerton C. Ross , Grotto Paolo 
Published: February 2007

AbstractThis is a retrospective analysis of children with metastatic soft tissue sarcoma (STS) registered in the major European STS studies: the SIOP MMT 75, the German CWS 1981 and 1986 studies, the Italian STS study, and the United Kingdom Children's Cancer Study Group centres in Britain. One hundred forty‐six patients out of 164 were evaluable in this analysis. The median age was 7 years (1–18) and the male/female ratio was 1.3:1. The median follow‐up was 80 months (7–171). The most common site of the primary tumor was the extremity (28%), which correlated well with the high preponderance (39%) of the alveolar type of RMS (aRMS). There was no dominant combination of metastatic sites and the most common single organ with metastasis was the lung (41%). Since the therapy depended on the country and period in which the patient was treated, we did not analyse the outcome and therapy together. Complete remission was achieved in 50% of the cases. Those with aRMS had a good chance of achieving CR (61%) but the majority of these patients relapsed (78%). The median time needed to relapse was 243 days (53 days to 47 months) for all patients. Analysis of the site of the primary tumor showed that the CR rate was best in the GU non‐BP site (62%) and worst in PM cases (35%). The overall survival and DFS rate were 18% and 15%, respectively. The GU non‐BP patients had a DFS rate of 50%, while the rate for all other sites varied between 12% and 18%. A total of 24 patients remained in CCR. The majority of them had embryonal type of RMS and metastases in only one anatomic site. Our analysis indicates that the best chance of prolonged survival was in metastatic GU non‐BP cases, patients with embryonal type RMS, and those with metastases in only one organ. To try to improve the treatment of metastatic STS, a prospective European cooperative study was started in 1989. © 1992 Wiley‐Liss, Inc.
Methylated catecholamine metabolites for diagnosis of neuroblastoma
Authors: Candito Mirande , Thyss Antoine , Albertini M. , Deville Anne , Politano Sabine , Mariani Roger , Chambon Pierre 
Published: February 2007

AbstractAssays of urinary catecholamines and their metabolites (HVA, VMA, dopamine) permit biochemical diagnosis of neuroblastoma in approximately 80% of patients. The urinary methylated catecholamine metabolites normetanephrine (NMN), metanephrine (MN), and 3‐methoxytyramine (3‐MT) were analyzed in 18 patients with neuroblastoma and compared with reference values established for 69 healthy pediatric controls. All 18 neuroblastoma patients had raised urinary excretion of at least one of the three commonly assayed metabolites (HVA, VMA, dopamine). Similarly, raised urinary excretion of a methylated metabolite was noted in all but one of the neuroblastoma patients. The 3‐MT level was pathologic in 16 of the 18 patients (89%). In this series, 3‐MT assay sensitivity was sufficient to warrant trials on a larger population including comparison with patients considered nonsecretors by routine assay procedures. © 1992 Wiley‐Liss, Inc.
Recovery from widespread bone marrow necrosis occurring after chemotherapy for adult acute monocytic leukemia
Authors: Sporn Jonathan R. , Fallon Margaret A. 
Published: February 2007

AbstractA patient with acute monocytic leukemia who developed bone marrow necrosis following induction chemotherapy is presented. Although the bone marrow necrosis was extensive, recovery occurred, along with complete remission of leukemia. Severe bone marrow necrosis in this setting may be reversible, and continued vigorous supportive care for these patients should be strongly considered. © 1992 Wiley‐Liss, Inc.
Reversal of radiation‐induced neutropenia by granulocyte colony‐stimulating factor
Authors: Marks Lawrence B. , Friedman Henry S. , Kurtzberg Joanne , Oakes W. Jerry , Hockenberger Beverly M. 
Published: February 2007

AbstractMyelosuppression is a common sequelae of radiotherapy, occasionally delaying the completion of treatment. In this report, we describe successful reversal of radiation‐induced neutropenia in a child receiving craniospinal irradiation by granulocyte colonystimulating factor (G‐CSF). We suggest that G‐CSF be considered as supportive care in patients in whom neutropenia develops during radiotherapy. © 1992 Wiley‐Liss, Inc.
Reversible hypophosphatemic rickets following ifosfamide treatment
Authors: Van Gool Stefaan , Brock Penelope , Wijndaele Godelieve , van de Casseye Willy , Kruger Marianne , Proesmans Willem , van Daele Maria Casteels 
Published: February 2007

AbstractA 7‐year‐old boy developed renal tubular dysfunction and hypophosphatemic rickets following treatment for relapsed embryonal rhabdomyosarcoma. Multi‐agent chemotherapy included ifosfamide; the child received a total of 108 g/m2. The complete Fanconi syndrome which ensued, including excessive loss of calcium, resolved spontaneously and progressively 18 months after the last dose of ifosfamide. The patient had no further symptoms of rickets and radiological signs had almost completely normalized. Further follow‐up was not possible as, despite further treatment, the child died of progressive disease. © 1992 Wiley‐Liss, Inc.
Lymphoma in Sjogren's syndrome
Authors: Pavlidis Nicholas A. , Drosos Alexandros A. , Papadimitriou Constantinos , Talal Norman , Moutsopoulos Haralampos M. 
Published: February 2007

AbstractSjogren's syndrome is an autoimmune disease with a known predisposition for lymphoma development. Eight of 120 patients with primary Sjogren's syndrome followed at the University of loannina over the past 7 years developed non‐Hodgkin's lymphoma diagnosed according to the Kiel classification. The lymphomas differed by location and grading. Six were called low grade (immunocytoma) and two intermediate grade non‐Hodgkin's lymphomas. Five of the immunocytomas involved the minor salivary or lacrimal glands. Immunoperoxidase staining for light chains revealed monoclonal populations. Two patients showed spontaneous regression not previously reported in Sjogren's syndrome. Thus, in Sjogren's syndrome, low grade non‐Hodgkin's lymphomas and especially immunocytomas are the most common lymphomas. These lymphomas tend to evolve very slowly and may regress spontaneously. Given these facts, a conservative approach to treatment is indicated in those patients with only localized disease. © 1992 Wiley‐Liss, Inc.
Smoking habits in survivors of childhood and adolescent cancer
Authors: Haupt Riccardo , Byrne Julianne , Connelly Roger R. , Mostow Eliot N. , Austin Donald F. , Holmes Grace R. , Holmes Frederick F. , Latourette Howard B. , Teta M. Jane , Strong Louise C. , Myers Max H. , Mulvihill John J. 
Published: February 2007

AbstractBecause of their increased risk for second cancers, childhood cancer survivors are people who really should not smoke, but available evidence suggests that they do. We studied the smoking habits of long‐term childhood cancer survivors in data collected from 1289 adult survivors of childhood cancer and 1930 of their sibling controls. Survivors were diagnosed with cancer between 1945 and 1974 when they were less than 20 years old. Using matched analyses that controlled for the influence of family, survivors were 8% less likely than controls to be current smokers, 13% less likely to be eversmokers, but 12% less likely to have quit smoking; these differences were not statistically significant. In a logistic regression analysis there was a significant difference by year of diagnosis for current smoking rate ratios (RR); survivors were less likely to be current smokers if diagnosed in recent years (RR = 0.76; 95% confidence intervals = 0.58–0.98, between 1965–74) and quite similar to controls if diagnosed in earlier years (RR = 1.05 between 1945 and 1954).In our group of long‐term cancer survivors, the reduction in current smoking came about because survivors were more inclined never to start smoking than controls. Once addicted to tobacco, they were less likely to quit. While the fact that survivors are less likely to start smoking is encouraging, the persistence of smoking habits strongly suggests the need for continuing efforts to prevent smoking in this most vulnerable group. © 1992 Wiley‐Liss, Inc.
Secretory breast cancer in childhood and adolescence: Report of a case and review of the literature
Authors: Serour Francis , Gilad Adi , Kopolovic Juri , Krispin Mayer 
Published: February 2007

AbstractA 17‐year‐old boy underwent a wide partial mastectomy with axillary dissection for secretory breast cancer, followed by low grade irradiation (30 Gy). There were no axillary lymph node metastases. Hormone receptor assay of the tumor was positive for progesterone and negative for estrogen. There was no local recurrence or sign of dissemination after nearly 5 years.Literature search revealed 21 cases of secretory breast cancer in childhood and adolescence; in only 2 cases was the hormonal status studied. We report an additional case and review the literature. © 1992 Wiley‐Liss, Inc.
Treatment of childhood acute myeloid leukaemia using the BFM‐83 protocol
Authors: Sartori Patricia C. E. , Taylor Mary H. , Stevens Michael C. G. , Darbyshire Philip J. , Mann Jillian R. 
Published: February 2007

AbstractThirty children presenting with acute nonlymphoblastic leukaemia from June 1984 to December 1989 were treated at one UK centre using a West German protocol, AML‐BFM‐83. This consisted of induction, an intensive outpatient‐based Consolidation regimen with seven different drugs and cranial irradiation, and Continuation therapy with thioguanine and cytosine arabinoside for 2 years with additional Adriamycin in the first year. Twenty‐five children achieved complete remission (83%). There were two early deaths from haemorrhage and infection and three from Induction failure. After a median follow‐up time of 60 months, nine relapses have occurred, all in the bone marrow. Life table analysis revealed a probability for survival at 5 years of 47%, event‐free survival 43%, and event‐free interval 50%. Median bed occupancy for chemotherapy and toxicity was 41 days, with median hospital stays of 29 days for Induction, 11 days for Consolidation and less than 1 day for Continuation. This data suggests that long‐term remissions can be achieved in just under half of children with acute nonlymphoblastic leukaemia while creating only modest demands on inpatient resources. © 1993 Wiley‐Liss, Inc.
Nephrotoxicity following carboplatin use in children: Is routine monitoring of renal function necessary?
Authors: Brandt Laura J. , Broadbent Valerie 
Published: February 2007

AbstractCarboplatin is an effective chemotherapeutic agent against many solid tumours. Although it is thought to be less nephrotoxic than its precursor cisplatin, current paediatric treatment protocols require regular monitoring of renal glomerular function during and after carboplatin use. Because accurate assessment of renal function in children requires measurement of isotope‐clearance glomerular filtration rates (GFRs), routine monitoring is costly and time consuming. We studied 26 paediatric patients who were receiving chemotherapy that included 500–600 mg/m2 of carboplatin per course. 51Cr‐EDTA GFRs were measured initially and after one to seven courses (median four). There was no measurable difference between renal function before and after carboplatin (P = 0.8). Our study shows that routine monitoring of renal glomerular function is unnecessary. Carboplatin use in patients who have had unilateral nephrectomy as part of their treatment is also discussed. Paediatric oncology literature concerning nephrotoxicity and carboplatin is reviewed. © 1993 Wiley‐Liss, Inc.
Phase II study of ifosfamide in childhood brain tumors: A report by the French society of pediatric oncology (SFOP)
Authors: Chastagner Pascal , Sommelet‐Olive Danièle , Kalifa Chantal , Brunat‐Mentigny Maud , Zucker Jean‐Michel , Demeocq François , Baranzelli Marie‐Christine , Tron Philippe , Bergeron Christophe , Pein François , De Lumley Lionel 
Published: February 2007

AbstractForty‐two evaluable pediatric patients with a variety of recurrent primary brain tumors participated in a phase II ifosfamide trial. Their mean age was 10 years. All patients were treated with ifosfamide, 3 g/m2/day for 2 days every 2 weeks. Response was assessed on clinical and radiological criteria after at least 2 courses of therapy. The overall response rate was 12% (5/42). One complete and 2 partial responses were documented in 21 patients with medulloblastoma. A partial response was demonstrated in 1 patient with primitive neurectodermal tumor (PNET) and in 1 patient with ependymoma. No activity was observed in astrocytic tumors.Toxicity was primarily neurologic (16 out of 54 patients, 30%). Hematological toxicity, without severe morbidity, was encountered in 9% of courses (16/179). Ifosfamide, administered at this dose regimen has modest efficacy in the treatment of recurrent childhood medulloblastoma and ependymoma and appears inactive for gliomas. Further trials with other dose schedules are necessary to assess the activity of this drug. However, according to the neurotoxicity observed in our trial, we would not recommend building a protocol using ifosfamide for highly progressive brain tumors. © 1993 Wiley‐Liss, Inc.
Alveolar rhabdomyosarcoma with the t(2;13): Cytogenetic findings and clinicopathologic correlations
Authors: Douglass Edwin C. , Shapiro David N. , Valentine Marc , Rowe Susan T. , Carroll Andrew J. , Raney R. Beverly , Ragab Abdel H. , Abella Steven M. , Parham David M. 
Published: February 2007

AbstractWe describe here the clinical and pathologic features associated with a specific translocation, t(2;13), in alveolar rhabdomyo‐sarcoma. Tumor specimens from 14 patients with a t(2;13)‐positive alveolar rhabdomyo‐sarcoma were studied for cytogenetic‐clinicopathologic correlations. Three patients had occult primary tumors; nine patients had primary tumors of the trunk (mediastinal, pelvic, or rectal). The presence of the t(2;13) was ascertained from examination of tumor involved bone marrow in ten patients who had widespread metastatic disease at the time of diagnosis. Marrow involvement was so extensive in three cases that they were initially diagnosed as acute leukemia. Response to therapy was poor, with only five patients achieving a complete response. Twelve patients have died of their disease at a median survival time of 6 months from diagnosis and one is living with recurrent disease; only one patient survives free of disease. © 1993 Wiley‐Liss, Inc.
Effective multi‐agent chemotherapy for advanced abdominal lymphoma and FAB L3 leukemia of childhood
Authors: Toogood Ian R. G. , Tiedemann Karin , Stevens Michael , Smith Peter J. 
Published: February 2007

AbstractBetween June 1981 and May 1988, 51 children with diffuse undifferentiated, advanced (Murphy Stage III and IV) intra‐abdominal non‐Hodgkin′s lymphoma were treated on an intensive multi‐drug chemotherapy protocol without irradiation to the primary tumour. Therapy was completed for Stage III disease at one year, but Stage IV patients continued with a further year of therapy until January 1986, when it was reduced to one year. Central nervous system (CNS) prophylaxis consisted of eight doses of intrathecal MTX for all children, and 24 Gy cranial irradiation for Stage IV patients only.There were 42 patients with Stage III disease (III A n = 29 and III B n = 13) and nine patients with Stage IV disease, of whom eight had extensive bone marrow and extramedullary disease (FAB L3 ALL). No patient had CNS disease at presentation.Forty‐eight of 51 children (94%) achieved a complete remission. Two children died during remission induction therapy and eleven children relapsed, mostly within eight months of diagnosis. All patients have completed therapy. Failure free survival is 76% for Stage III and 67% for Stage IV patients, with a median followup of 90 and 64 months, respectively. Subdividing Stage III patients into Stage III A and III B did not show significantly different survival (P = 0.9), but the number of patients in Stage III B is small. These results compare favourably with the most effective published protocols, and toxicity has been manageable. © 1993 Wiley‐Liss, Inc.
Clinical phenotypes and Wilms tumor
Authors: Clericuzio Carol L. 
Published: February 2007

AbstractWilms tumor can occur in association with a number of recognizable patterns of malformation, as first described by Miller et al. in 1964 [1]. This paper represents a synthesis of the current state of knowledge regarding recognizable phenotypes associated with Wilms tumor. Specific disorders discussed include the Beckwith‐Wiedemann syndrome, which has been localized to 11p15.5; isolated hemihypertrophy; sporadic aniridia, which is almost always associated with del(11p13); genital anomalies, particularly male pseudohermaphroditism and the Denys‐Drash syndrome; and more weakly associated or uncommon conditions, such as neurofibromatosis and Perlman syndrome, respectively. Wilms tumor (WT) surveillance for specific high risk phenotypes should include a rational schedule of abdominal ultrasound examinations, taking into account the epidemiology of WT associated with specific disorders. Physical examination, with emphasis on abdominal palpation, and urinalysis should also be performed on a rational schedule. The schedule of examinations needs to be arrived at with input from clinical geneticists, oncologists, epidemiologists and pathologists with WT expertise. Lastly, care‐takers of high risk individuals should be taught abdominal palpation, to be performed daily at home. © 1993 Wiley‐Liss, Inc.
Rare tumors in childhood: Pathological aspects. Experience of the Kiel pediatric tumor registry
Authors: Harms Dieter , Schmidt Dietmar 
Published: February 2007

AbstractA wide variety of rare tumors can occur in childhood and adolescence. Tumors can be rare in any age group; common tumors of adults can appear in childhood and adolescence, and many rare tumors and tumor‐like lesions show a predilection for younger age groups. Comparatively frequent tumors can present with rare histologic features or can occur in rare atypical locations, and, finally, seemingly common but, in fact, rare tumors have to be distinguished from truly common but rarely recognized tumors. Thus, the spectrum of rare tumors is broad, reflecting the fluent reality of life. © 1993 Wiley‐Liss, Inc.
Langerhans cell histiocytosis in childhood: Results from the Italian cooperative AIEOP‐CNR‐H.X '83 study
Authors: Ceci Adriana , De Terlizzi Marino , Colella Roberto , Loiacono Giuseppe , Balducci Donato , Surico Giammarco , Castello Manuel , Testi Anna Maria , De Bernardi Bruno , Indolfi Paolo , Macchia Pierantonio , Madon Enrico , Mancini Antonia , Rosati Domenico 
Published: February 2007

AbstractNinety patients with biopsy‐proven Langerhans cell histiocytosis (LCH) were enrolled from June, 1983, to December, 1988, in the multicenter AIEOP‐CNR‐H.X. '83 study. They were divided into two groups: poor prognosis (PP), comprising 11 children with organ dysfunction (OD), and good prognosis (GP), made up of 79 patients without OD. Eighty‐four patients were evaluable for treatment results. Among GP patients, 16 with a single lesion received only local treatment, while 59 entered a clinical trial of immunotherapy and/or monochemotherapy with vinblastine (VBL). Nonresponders, sequentially received doxorubicin (ADM) and then etoposide (VP16). PP patients were treated with 4 week cycles of vincristine, ADM, cyclophosphamide, and prednisone for nine courses. The overall survival was 92.8% (100% for GP patients and 45.5% for PP patients) at 48 months. The complete response (CR) rates for immunotherapy, VBL, ADM, and VP16 were 10%, 62.9%, 42.8%, and 88.2%, respectively. Two of the 11 PP patients had a CR (18.2%), while six died and three are still alive with recurrent disease. The overall incidence of disease‐related disabilities was 47.7%, while that of diabetes insipidus was 20%. Monochemotherapy is probably adequate in GP patients, while more effective treatments are needed for PP patients. © 1993 Wiley‐Liss, Inc.
The treatment of malignant scala posterior tumors in children: II. Preliminary result of the pre‐ and postoperative adjuvant chemotherapy of scala posterior tumors
Authors: Schuler Dezsõ , Somló Pál , Koós Rozália , Kálmánchey Rozália , Paraicz Ervin 
Published: February 2007

AbstractTen children with posterior scala tumor infiltrating the surrounding brain substance and/or the brain stem entered in the present study with preoperative chemotherapy. In 8 of the 10 cases regression and necrosis of the tumor were seen by CT examination after the preoperative therapy. The diameter of the tumor decreased on the average by 35.6% (14.0–74.3%). The main side effect was granulocytopenia. According to our observation, the preoperative therapy enables a more radical surgery in some cases of medulloblastoma and ependymoma. Further observations are necessary to confirm these preliminary results. © 1993 Wiley‐Liss, Inc.
Cerebral non‐Hodgkin's lymphoma discovered when treating Hodgkin's disease
Authors: Bergeron Christophe , Le Moine Philippe , Le Prise‐Fleury Elisabeth Le , Jouan Hélène , Tass Patrick , Darcel Françoise , Chatel Marcel , Edan Christine , Patte Catherine , Faivre Jean , Gall Edouard Le 
Published: February 2007

AbstractCase report of the appearance of a highly malignant cerebral non‐Hodgkin's lymphoma of a diffuse large cell type, type B, occurring at the immediate onset of chemotherapy for a stage IV (mediastino‐pulmonary) Hodgkin's disease (nodular sclerosis) diagnosed in a 16‐year‐old boy. The treatment of this cerebral lymphoma associated primary chemotherapy with high dose methotrexate, high dose aracytine, etoposide, and ifosfamide. The chemotherapy proved to be highly efficient, producing complete remission. Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non‐Hodgkin's lymphoma. This treatment was followed by 36 Gy of cerebral irradiation. Thirty‐six months after the discovery of the cerebral non‐Hodgkin's lymphoma the patient was still disease‐free and doing well. © 1993 Wiley‐Liss, Inc.
Hodgkin's disease associated with central pontine myelinolysis
Authors: Chintagumpala Murali M. , Mahoney Donald H. , McClain Kenneth , Dreyer Zoann E. , Fishman Marvin A. , Carrol Clark L. , Steuber Charles P. 
Published: February 2007

AbstractWe describe a 12‐year‐old black male who presented with cervical lymphadenopathy, hepatosplenomegaly of 3 months duration, and ataxia and incoordination of recent onset. Hodgkin's disease, stage IVB, was diagnosed. An MRI of the head demonstrated a nonenhancing, well‐defined pontine lesion. The pontine lesion and the associated neurologic symptoms were consistent with central pontine myelinolysis. Treatment of Hodgkin's disease resulted in complete remission and complete disappearance of the pontine abnormality. © 1993 Wiley‐Liss, Inc.